Industry
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
Total Trials
3
Recruiting
3
Active
3
Completed
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
Failure Rate
0.0%
0 terminated/withdrawn out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed trials have results
Key Signals
3 recruiting
Enrollment Performance
Analytics
Phase 1
3(100.0%)
3Total
Phase 1(3)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT07413328Phase 1Recruiting
HWS116 Monotherapy in Patients With Advanced Solid Tumors
Role: lead
NCT07373457Phase 1Recruiting
A Phase I Study of HW201877 in Healthy Subjects
Role: lead
NCT06882135Phase 1Recruiting
HW071021 Monotherapy in Patients With Advanced Solid Tumors
Role: lead
All 3 trials loaded